In one paragraphArticle in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
7 authors.
Rahul L BodkheDepartment of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-7902-3357 Rebecca B BlankDivision of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-6292-6947 Kai R TrepkaDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-8672-6317 Diego A OrellanaDepartment of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, USA.
Jose U ScherDivision of Rheumatology, Department of Medicine, NYU Grossman School of Medicine, New York, NY, USA.ORCID 0000-0002-1072-6994 Peter J TurnbaughDepartment of Microbiology & Immunology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0888-2875 Renuka R NayakDepartment of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1123-4668 Funding
Project-005UL1TR001445 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BREDELLA, MIRIAM ANTOINETTE, HOCHMAN, JUDITH S · 2015 to 2025
$103.5MPredicting and preventing drug metabolism by the human gut microbiomeR01HL122593 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Peter James Turnbaugh · 2016 to 2026
$5.7MEmploying the gut microbiome to accelerate effective initiation of rheumatoid arthritis therapyR01AR074500 · NIAMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Renuka Rajendra Nayak, Jose U. Scher · 2019 to 2026
$4.1MMetabolism of cancer chemotherapeutics by the human gut microbiomeR01CA255116 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Peter James Turnbaugh · 2023 to 2026
$3.1MFrom here to eternity: gut microbial response to drug therapy and inflammationR35GM151349 · NIGMS · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI Renuka Rajendra Nayak · 2023 to 2026
$1.5MThe impact of the gut microbiome on rheumatoid arthritis treatmentK08AR073930 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAYAK, RENUKA RAJENDRA · 2018 to 2022
$981kMicrobial metabolites impacting the response to methotrexate in rheumatoid arthritisR03AR082036 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAYAK, RENUKA RAJENDRA · 2023 to 2024
$159kCSRD VA I01 CX002557NCATS NIH HHS UL1 TR001445NCI NIH HHS R01 CA255116NHLBI NIH HHS R01 HL122593NIAMS NIH HHS K08 AR073930NIAMS NIH HHS R01 AR074500NIAMS NIH HHS R03 AR082036NIGMS NIH HHS R35 GM151349
6 · The paper itselfAbstract
The human gut microbiome influences treatment outcomes, but whether microbiome signatures of drug response generalize across cohorts remains unclear. Here, we perform a multi-cohort analysis (3 cohorts, N=100 patients) to determine whether cross-cohort microbial signatures are associated with methotrexate (MTX) response in new-onset rheumatoid arthritis (RA) patients. Pre-treatment gut microbiome community structure and function differed by future MTX response status, with MTX-nonresponders (MTX-NR) showing
Identifiers
PMID41959277
PMCPMC13060180
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390